STUDY QUESTION: Is oral glucose tolerance test (OGTT) needed in all women with polycystic ovary syndrome (PCOS)?
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive-aged women, with a prevalence of 15-20% when the Rotterdam criteria are used for diagnosis (Lauritsen et al., 2014) . The presence of at least two of the following criteria is needed for the diagnosis when other causes are excluded: (i) oligoamenorrhea, (ii) hyperandrogenism (biochemical or clinical) and (iii) polycystic ovaries (PCO) on ultrasound. PCOS is associated with obesity and insulin resistance, which lead to increased risk of prediabetes, defined as impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), and Type 2 diabetes (T2D) (Ehrmann et al., 1999) .
The recommendation of oral glucose tolerance test (OGTT) in newly diagnosed PCOS varies between different guidelines (Table I) . Some guidelines recommend mandatory OGTT for all women with the diagnosis (Legro et al., 2013; Goodman et al., 2015;  Jean Hailes for Women's Health on behalf of the PCOS Australian Alliance, 2015), whereas others include BMI, previous gestational diabetes or a family history of T2D in the decision model before the recommendation of OGTT (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004; Wild et al., 2010; RCOG, 2014) . It is still debated whether risk of prediabetes and T2D is increased due to PCOS per se, or if obesity is the main risk factor (Ehrmann et al., 1999; Ollila et al., 2017) . Increasing age is associated with loss of beta cell function (Bryhni et al., 2010) and age > 40 years has been chosen as a separate risk factor for T2D in several guidelines (RCOG, 2014; Goodman et al., 2015) . Recently, Ollila et al. reported that none of 62 lean women with self-reported PCOS developed T2D by 46 years-of-age and the results suggested that OGTT screening should be targeted to overweight and obese women with PCOS (Ollila et al., 2017) . However, the study findings need to be confirmed in PCOS study populations with a wider range of BMI, age and well described PCOS phenotypes.
The aim of this study was to investigate the risk of prediabetes and T2D according to BMI, age, androgen concentration and Rotterdam phenotype in a large, well-characterized Nordic patient population with PCOS.
Materials and Methods

Inclusion criteria
Women diagnosed with PCOS from Denmark, Finland, Norway and Sweden who had at least one OGTT assessment were included in this study. All women fulfilled the Rotterdam criteria for PCOS (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) and were of Nordic origin. In 211 women, OGTT had been performed upon diagnosis of PCOS as part of clinical care, and the remaining 665 women had been tested with OGTT during research projects and clinical trials that have previously been published (Piltonen et al., 2004; Puurunen et al., 2009 Puurunen et al., , 2013 Hudecova et al., 2011a,b; Nybacka et al., 2011; Glintborg et al., 2012; Morin-Papunen et al., 2012) . All women were recruited from outpatient clinics or hospitals.
Included women with PCOS were grouped into four different phenotypes according to the Rotterdam criteria: Phenotype A: All three Rotterdam criteria present; Phenotype B: Hyperandrogenism and oligomenorrhoea; Phenotype C: Hyperandrogenism and PCO and Phenotype D: Oligoamenorrhoea and PCO (Azziz et al., 2006) .
Exclusion criteria
The use of hormonal contraceptives in the past 2 months prior to enrollment, ongoing pregnancy or breastfeeding, or other serious endocrine diseases. Women paused metformin minimum one month before the study. In daily clinic, OGTT is not performed in patients with a diagnosis of diabetes, and therefore women with previously diagnosed diabetes (Type 1 or 2) were excluded from the present study.
Ethical approval
Informed consent was obtained from women participating in clinical trials at the original study sites. The trials were all approved by the Ethics Committees of the respective study sites.
Examinations
The subjects underwent clinical examination: height, weight (calculation of BMI), waist circumference, Ferriman-Gallwey (FG)-scoring for hirsutism and transvaginal ultrasound. Clinical hyperandrogenism (hirsutism) was diagnosed when a subject had a FG score of over seven. A standard 2 h OGTT was performed after an overnight fast on any day of the menstrual cycle. Fasting and 2 h plasma glucose concentrations were measured at baseline and 2 h after a 75 g glucose load. Hemoglobin A1c (HbA1c) was measured in 393 patients. The patients were classified into different stages of glucose tolerance according to the American Diabetes Association (ADA) guidelines: Normal glucose tolerance (NGT) was fasting glucose ≤5.5 mmol/l and 2 h glucose <7.8 mmol/l, IFG: Fasting glucose 5.6-6.9 mmol/l and normal 2 h glucose, IGT: Normal fasting glucose and 2 h glucose 7.8-11.0 mmol/l, T2D was defined as fasting glucose ≥7.0 mmol/l or 2 h glucose ≥ 11.1 mmol/l, or HbA1c ≥ 6.5% (American Diabetes Association, 2016). Prediabetes was defined as IFG or IGT or HbA1c ≥ 5.7 but ≤6.4%.
Serum analysis
The analysis methods of serum testosterone and sex hormone-binding globulin (SHBG) levels differed between research centres as described below. Total testosterone (TT) and SHBG were measured with immunoassays. Denmark: Serum TT was analyzed using a specific radioimmunoassay after extraction, SHBG was measured by autoDELFIA assay (AutoDELFIA, PerkinElmer Life Sciences, Oy, Turku, Finland) (Glintborg et al., 2015) . Norway: TT and SHBG were analyzed with Roche Modular E170 immunoassay, using kits from Roche. Finland: Serum concentrations of testosterone were analyzed using an automated chemiluminescence system (Advia Centaur; Bayer Healthcare LCC, Diagnostic Division, Terrytown, NY Advia) (Piltonen et al., 2004) or using the liquid chromatography/mass spectrometry method. Agilent triple quadrupole 6410 LC/MS equipment with an electrospray ionization source operating in positive-ion mode (Agilent Technologies, Wilmington, DE, USA) (Puurunen et al., 2009 (Puurunen et al., , 2013 Morin-Papunen et al., 2012) . SHBG was analyzed by chemiluminometric immunoassay (Immulite 2000, Siemens Healthcare, Llanberis, UK) (Piltonen et al., 2004; Puurunen et al., 2009 Puurunen et al., , 2013 Morin-Papunen et al., 2012) . Uppsala, Sweden: Serum concentrations of TT and SHBG were analyzed by solid-phase chemiluminescent immunometric assays and oestradiol was measured by competitive immunoassay, using commercial kits obtained from Siemens Medical Solutions, Germany (Hudecova et al., 2011a,b) . Stockholm, Sweden: TT was determined by radioimmunoassay, SHBG by chemiluminescent enzyme immunometric assays using commercial kits (Nybacka et al., 2011) . Free androgen index (FAI) was calculated by dividing TT with SHBG and multiplying by 100.
Statistics
The Shapiro-Wilks test was used to assess normal distribution of variables. None of the variables were normally distributed and data were presented as median (interquartile range). The Kruskal-Wallis test was used to compare differences in continuous variables between patient groups and the Chi-squared test was used to test for differences in frequencies between groups. Linear regression analyses were used to correct for differences in BMI and age between patient groups.
We performed multiple regression analyses to test the association between 2 h glucose during OGTT as the dependent variable and age, BMI, and metabolic risk markers or PCOS phenotype as the explanatory variables. We used SPSS version 21.0 (SPSS, Chicago, IL, USA) in our calculations. P-values < 0.05 were considered significant.
Results
Characteristics
A total of 876 premenopausal women with PCOS were included in the study. Clinical and biochemical characteristics of the study population are presented in Table II . The age range of the women was 14-57 years. The prevalence of BMI ≥ 25 kg/m 2 was 66% (578/876).
Prevalence of prediabetes and T2D
In the whole study group, 3% (23/876) had T2D, 12% (101/876) had IGT, 11% (99/876) had IFG, 23% (204/876) had prediabetes (four women were diagnosed based on HbA1c) and 74% (649/876) had NGT. Characteristics of women according to glucose tolerance status are presented in Table II .
BMI and waist
The prevalence of prediabetes and T2D associated with an increase in BMI and waist circumference. T2D was not diagnosed in any of the women with BMI < 25 kg/m 2 or waist circumference <88 cm. 91% of the women (21/23) with T2D had BMI ≥30 kg/m 2 .
Age
Age was higher in women with prediabetes and T2D compared to NGT, but the distribution of T2D, prediabetes, and NGT was comparable in women grouped by age below or above 40 years (Table II) .
Figs 1 and 2 shows the risk of T2D, prediabetes, and NGT within different age groups. In women with BMI ≥25 kg/m 2 (Fig. 2) , the association of IGT increased with increasing age and in women aged ≥45 years 47% (7/15) had prediabetes. Table III shows data in women according to Rotterdam phenotype. The risk of T2D did not differ between phenotypes, whereas the risk of prediabetes was highest in women with phenotype A. As expected, BMI, age and testosterone levels differed significantly between the four phenotypes. Women of type D phenotype had lower BMI and testosterone levels. We performed multiple regression analyses to test the independent effect of different Rotterdam criteria and PCOS phenotypes on 2 h glucose levels after correcting for BMI and age (Table IV) . The individual Rotterdam criteria or PCOS phenotype were not independent predictors of 2 h glucose levels.
PCOS phenotypes
Discussion
In this large study on well-characterized Nordic women with PCOS, T2D was not diagnosed in any woman with BMI < 25 kg/m 2 or waist circumference <88 cm. Our data suggest that OGTT is not required in Nordic lean women, independent of risk factors. The present data was cross-sectional, but the age span covered 14-57 years. Age ≥40 years was not a risk factor for T2D, however, the prevalence of prediabetes was positively associated with age in overweight and obese women. Overall, the prevalence of T2D was low (3%) and 91% of women with T2D had BMI ≥30 kg/m 2 . The individual Rotterdam criteria, including testosterone levels or PCOS phenotype (A-D), were not independent predictors of 2 h glucose levels.
BMI and T2D in PCOS
The present data support the findings reported by Ollila et al. in a Finnish study population where PCOS was self-reported in 279 women, and none of the lean women with PCOS had T2D at the age of 46 years, based on OGTT (Ollila et al., 2017) . The present study was three times larger than the Finnish study and we thoroughly examined all included women, which gave us the possibility to further investigate the possible modifying effects of waist, testosterone levels, and PCOS phenotype on the risk of T2D in PCOS. The present data support the conclusion by Ollila et al. that the risk of T2D in women with PCOS is mainly due to overweight and obesity (Ollila et al., 2017) . However, in our study population the prevalence of T2D was 3%, while the Finnish study reported a prevalence of 12%. respectively), but the two populations differed in mean age (29 vs 46 years, respectively). Previous studies have revealed that European populations with PCOS have a relatively low risk of T2D (1.5%, mean age 29 years, BMI 27.3 kg/m 2 in a Danish population based study) (Glintborg et al., 2015) , whereas two previous studies from USA and one Australian community-based cohort analysis reported T2D prevalence of 10% (mean age 26.5 years, BMI 37.1 kg/m 2 ) (Ehrmann et al., 1999) , 7.5% (mean age 28 years, BMI 32.9 kg/m 2 ) (Legro et al., 1999) , and 5.1% (mean age 20.5 years, BMI 28.0 kg/ m 2 ) (Joham et al., 2014) .
Our finding that BMI was an important predictor of diabetes risk in PCOS was also supported by several smaller studies including <100 women with PCOS. Norman et al. found that BMI was an independent significant predictor of adverse change in glycemic control during 6.2 years follow-up (Norman et al., 2001) and Boudreaux et al. found that the excess risk of T2D was largely confined to morbidly obese women during 8 years follow-up (Boudreaux et al., 2006) . Also Celic et al. discovered that conversion from normal to abnormal glucose tolerance was increased in PCOS and obese women with PCOS had a 4-fold increase in their risk of developing IGT compared with non-obese women with PCOS (Celik et al., 2014) . A meta-analysis identified an OR of 2.54 for IGT and 4.0 for T2D in women with PCOS compared to controls in BMI-matched studies (Moran et al., 2010) . Nevertheless, the magnitude of risk for IGT and T2D in PCOS is unclear as most studies were cross-sectional, relatively small and lacked concurrently studied control women (Moran et al., 2010; American Diabetes Association, 2016) . Our results are valid for the Nordic countries, and it is necessary to study other populations/ethnic groups with PCOS. PCOS, polycystic ovary syndrome; P-adj, P-adjusted; T2D, Type 2 diabetes; NGT, normal glucose tolerance; FAI, free androgen index. Phenotype A: All three Rotterdam criteria fulfilled, phenotype B: Hyperandrogenism and oligomenorrhea, Phenotype C: Hyperandrogenism and PCO, phenotype D: Oligomenorrhea and PCO. Data presented as n (%) or median (interquartile range). P-adj: P-value adjusted for age and BMI.
Age and T2D in PCOS
Women with prediabetes and T2D were older than women with NGT in the present study, but age ≥ 40 years was not associated with increased prevalence of prediabetes or T2D. We observed that the prevalence of prediabetes was unchanged according to age in women with BMI < 25 kg/m 2 , whereas the prevalence of prediabetes increased in older age groups with BMI ≥ 25 kg/m 2 . These findings supported an important interaction between BMI, age and diabetes risk. Generally, T2D develops due to decreased β-cell function and increased insulin resistance (Tabák et al., 2009) . β-cell function worsens with advancing age (Bryhni et al., 2010) , but women with more severe insulin resistance will be more prone to develop T2D than women without insulin resistance. As a group, women with PCOS are more insulin resistant than controls and thus have a higher load on the β-cell function. Increasing age is associated with higher BMI and waist circumference (Glintborg et al., 2012) , which could contribute to explain why age was not an independent predictor of 2 h glucose levels in the multiple regression analysis in the present study. The possible separate impact of age on the risk for prediabetes and T2D in PCOS needs to be examined in long-time prospective studies.
Prediabetes in PCOS
Prediabetes is an important independent risk factor for diseases associated with T2D, like cardiovascular diseases, neuropathy and nephropathy (Ferrannini, 2014) . The presence of prediabetes may therefore indicate the need for intensified prospective screening for T2D as glucose levels can return to normal range after life style intervention (Tuomilehto et al., 2001) . Prediabetes was defined as IGT or IFG and the prevalence of IGT and IFG was 5 and 6% in the present study. The risk of progression from IGT to T2D is, however, five times higher than the risk of progression from IFG to T2D with no significant increased risk of developing T2D from IFG compared to NGT (Ferrannini et al., 2009) . Also for PCOS patients, it has been shown that NGT progresses to T2D through a gradual decline of β-cell function rather than further increase in insulin resistance (Dunaif and Finegood, 1996; Hudecova et al., 2011a,b) .
HbA1c in PCOS
The optimal screening method for T2D in PCOS remains to be determined. HbA1c compared to OGTT had low sensitivity for the diagnosis of prediabetes and T2D in PCOS (Magnussen et al., 2011) , but HbA1c could be a better predictor of cardiovascular disease and overall mortality than fasting or 2 h glucose (Magnussen et al., 2011; Rezaee et al., 2016) . It has been suggested that HbA1c ≥ 5.7% could be used as an indicator for increased metabolic risk in PCOS (Rezaee et al., 2016) and prospective screening with HbA1c is much more feasible than OGTT in a clinical setting.
PCOS phenotypes and T2D
We did not find any association between PCOS phenotypes and T2D. However, the risk of prediabetes was highest in women of PCOS phenotype A (fulfilling all Rotterdam criteria), but in multiple regression analyses, testosterone levels, menstrual regularity, or the presence of PCO did not independently predict 2 h glucose levels after adjustment for BMI and age. Again, our findings support that BMI was the most important risk factor for diabetes in women with PCOS. The importance of PCOS phenotype for metabolic risk is debated. It was suggested that patients fulfilling the National institute of Health (NIH) criteria for PCOS could have a more adverse metabolic risk than patients with milder phenotypes (Moran et al., 2015) and that metabolic disturbances were more pronounced in hyperandrogenic women with PCOS compared to patients with no hyperandrogenaemia (Corbould, 2008) . We found that BMI and waist circumference differed significantly between PCOS phenotypes A-D and women of phenotype D had lower BMI and waist circumference than phenotypes A-C. The results of the present study were in accordance with a Chinese study of 2436 women with PCOS reporting no impact of PCOS phenotype on glucose tolerance (Li et al., 2016) . Future studies regarding metabolic risk in different PCOS phenotypes need to adjust for differences in BMI.
Strengths and limitations
The strength of this study is a large well-characterized population of women with PCOS from a multicenter study and that women were Data presented as unstandardized B-value (P-level). *P < 0.05; **P < 0.001.
grouped according to BMI, age and phenotype. Limitations of this study was that it was cross-sectional, and hence we cannot make recommendations as to how often women with PCOS should be tested prospectively, hence longitudinal studies are needed. Ethnicity is an important factor in the development of prediabetes and T2D (Wells et al., 2016 ) and therefore we only included women of Nordic origin. The findings of the present study may not apply for study populations of other origins. Testosterone was analyzed by high-quality assays, but by different laboratories, which could have affected study results. In accordance with other studies, we performed one OGTT in each study participant, whereas the diagnosis of T2D needs confirmation with a new OGTT or HbA1c (American Diabetes Association, 2016). Previous studies described considerable day to day variation in OGTT results (Schousboe et al., 2002) and the performance of a second OGTT in women with prediabetes or T2D would result in lower risk of T2D in PCOS. The addition of another OGTT would, however, not change our primary study conclusion.
In conclusion, T2D was not diagnosed in any women with PCOS and BMI < 25 kg/m 2 or waist <88 cm. Age was not a risk factor for T2D in lean women with PCOS. These findings support that an OGTT is not routinely needed in lean women with PCOS. The risk of diabetes was not affected by PCOS phenotype after correcting for BMI and age.
